Search by Drug Name or NDC
NDC 00299-5980-45 Mirvaso 5 mg/g Details
Mirvaso 5 mg/g
Mirvaso is a TOPICAL GEL in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Galderma Laboratories, L.P.. The primary component is BRIMONIDINE TARTRATE.
Product Information
| NDC | 00299-5980 |
|---|---|
| Product ID | 0299-5980_fda53493-1917-4c14-988b-bec8814c37c8 |
| Associated GPIs | 90060020104020 |
| GCN Sequence Number | 071362 |
| GCN Sequence Number Description | brimonidine tartrate GEL (GRAM) 0.33 % TOPICAL |
| HIC3 | L5G |
| HIC3 Description | ROSACEA AGENTS, TOPICAL |
| GCN | 35124 |
| HICL Sequence Number | 011786 |
| HICL Sequence Number Description | BRIMONIDINE TARTRATE |
| Brand/Generic | Brand |
| Proprietary Name | Mirvaso |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | brimonidine tartrate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | GEL |
| Route | TOPICAL |
| Active Ingredient Strength | 5 |
| Active Ingredient Units | mg/g |
| Substance Name | BRIMONIDINE TARTRATE |
| Labeler Name | Galderma Laboratories, L.P. |
| Pharmaceutical Class | Adrenergic alpha-Agonists [MoA], alpha-Adrenergic Agonist [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA204708 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00299-5980-45 (00299598045)
| NDC Package Code | 0299-5980-45 |
|---|---|
| Billing NDC | 00299598045 |
| Package | 45 g in 1 TUBE (0299-5980-45) |
| Marketing Start Date | 2013-08-23 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |